Global Proteomic Profiling of Pediatric AML: A Pilot Study.

Area of Science:

• Proteomics
• Oncology
• Pediatric Hematology

Background:

• Acute Myeloid Leukemia (AML) is a complex cancer with diverse genetic features.
• Understanding proteomic differences is crucial as proteins drive cellular functions and are drug targets.
• Limited proteomic studies exist for pediatric AML, especially concerning cytogenetic variations.

Purpose of the Study:

• To investigate global proteomic profiles in pediatric AML.
• To compare proteomes based on core binding factor (CBF) translocation, minimal residual disease (MRD1), and cytarabine sensitivity.
• To identify potential therapeutic protein targets in pediatric AML.

Main Methods:

• Pilot study using TMT-LC/LC-MS/MS platform on leukemic cells from 16 pediatric AML patients.
• Proteomic data analyzed for differences between CBF and non-CBF AML subtypes.
• Correlations explored with MRD1 status and in vitro cytarabine sensitivity (Ara-C LC50).

Main Results:

• Significant proteomic differences were observed between CBF and non-CBF pediatric AML subtypes.
• Identified potential druggable proteomic targets including THY1 (CD90), CTSF, ANPEP (CD13), and MMP14.
• Proteomic insights into AML subtype physiology were gained.

Conclusions:

• Proteomic profiling offers valuable insights into pediatric AML heterogeneity.
• Distinct proteomic signatures exist for different AML subtypes, guiding personalized medicine.
• Identified protein targets warrant further investigation for novel therapeutic strategies in pediatric AML.